# Creative Medical Technology Holdings

Creative Medical Technology Holdings is an Asset Manager based in Phoenix, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Phoenix, United States
- **Region:** North America
- **Address:** Phoenix, AZ, United States
- **Assets under management:** Undisclosed
- **Website:** creativemedicaltechnology.com

## Regulatory record

- **Reports private funds:** No

## About

Creative Medical Technology Holdings operates as a publicly traded biotechnology entity. Led by CEO Timothy Warbington, the firm focuses on stem cell-based regenerative medicine, with a specific emphasis on conditions underserved by conventional treatments. Its primary clinical programs target urological disorders such as erectile dysfunction and urinary incontinence, alongside broader immunological applications. The firm's strategy centers on advancing its proprietary Celzyme platform, which uses amniotic fluid-derived stem cells and their exosomes. Key assets in the pipeline include CaverStem for erectile dysfunction, FemCelz for female sexual health, and StemSpine for degenerative disc disease. Clinical focus remains on early and mid-stage trials, with direct funding sourced via Nasdaq-listed equity and minimal reliance on traditional venture capital structures. Operational footprint is largely concentrated in the United States, with executive leadership based in Phoenix, Arizona. The firm maintains a lean organizational structure typical of a pre-revenue biotech. As of mid-2024, Creative Medical Technology filed regulatory submissions to expand clinical trial enrollment and has disclosed ongoing preclinical work extending its regenerative platform into immunology and chronic kidney disease models. A structural differentiator for Creative Medical Technology is its access to public capital markets at a clinical-stage valuation, bypassing the private funding rounds that characterize most firms of equivalent maturity. This allows a continuous fundraising posture but subjects the firm to the volatility and disclosure requirements of the Nasdaq, creating a governance profile distinct from typical R&D-stage private companies.

## Sectors

- Healthcare Services
- Digital Health

## People

- Timothy Warbington — CEO

## Questions

### What is Creative Medical Technology Holdings' core therapeutic focus?

The firm develops regenerative cell therapies derived from amniotic fluid. Its most advanced programs target urological and sexual health conditions, including erectile dysfunction and female sexual dysfunction, using its Celzyme technology platform.

### How does the firm's public listing affect its investment profile?

Because it is publicly traded (Nasdaq: CELZ), the firm's equity is available for institutional and retail purchase directly on the open market. This structure differs from typical allocations to private biotech funds, providing liquidity but also exposing investors to microcap stock volatility.

### Who makes the strategic decisions for the firm?

Timothy Warbington serves as the Chief Executive Officer and is the named principal responsible for corporate and clinical development strategy. A board of directors provides formal governance for the public entity.

### What stage of clinical development is the company currently in?

Creative Medical Technology operates in early to mid-clinical stages. Its programs rely on FDA approvals for investigational new drug applications and continued clinical trials. As of 2024, the firm has not yet commercialized a product or recorded material revenue.

## Related profiles

- [Morien Resources](https://altss.com/profile/morien-resources-corp)
- [OriginClear](https://altss.com/profile/originclear-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/creative-medical-technology-holdings-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology